CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 76 enrolled
Drug / intervention
Testosterone Cream +1 moredrug
Likely dose
Estring 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00698035
NCT00698035Phase 2Completed
CompareCT.gov

A Phase II Study of Vaginal Testosterone Cream vs. the ESTRING for Vaginal Dryness or Decreased Libido in Early Breast Cancer Patients Treated With Aromatase Inhibitors

University of California, San Francisco·interventional·Posted Jun 16, 2008·Updated Jun 2, 2014

In Brief

A Phase 2 clinical trial evaluating Testosterone Cream and Estring for Sexual Dysfunction, Physiological. Completed, enrolled 76 participants across 1 site.

Detailed Summary

The purpose of this clinical research study is to determine whether the ESTRING or a special preparation of a testosterone cream inserted vaginally are safe for use in breast cancer patients. This study will also evaluate if either of these treatments can improve symptoms of vaginal dryness or decreased sexual interest that are related to your treatment for breast cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSexual Dysfunction, Physiological
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 16, 2008
Enrollment StartMar 1, 2007
Primary CompletionOct 1, 2012
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 18.0 years ago

Interventions

Testosterone Creamdrug

1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment

Estringdrug

2mg ring inserted vaginally once every 12 weeks